PD-1 Resistant Head and Neck Cancer: Evolving Therapeutic Approaches
PD-1 inhibitors have improved outcomes for many patients with head and neck cancer, yet resistance remains a major challenge. Researchers and clinicians are exploring new therapeutic strategies to overcome this barrier, focusing on tumor biology, immune system interactions, and genetic mutations. Combination therapies involving immunomodulators, targeted agents, and radiation are showing promising results by enhancing immune response and disrupting cancer cell survival pathways.
Advanced molecular profiling helps identify resistance mechanisms and allows physicians to tailor treatments. Novel therapies such as personalized cancer vaccines, T-cell therapies, and dual-checkpoint inhibitors aim to re-sensitize tumors to immune attack. Imaging innovations and AI-driven analytics assist in tracking tumor evolution and predicting treatment response.
By leveraging precision medicine and immune system reprogramming, the medical field is gradually improving outcomes for patients with PD-1 resistant head and neck cancer.
